EnZeta Immunotherapies
Coral Gables, US · Founded 2023 · Delaware corporation
Founders & leadership
PK
Paul KellyExecutive
TS
Traversa SergioNamed on SEC filing
Board
ST
Sergio TraversaBoard director
Reported raises · per SEC filings
Form D private placements$855K disclosed across 3 rounds · 2023–2025
▶$840KraisedMar 2026 · 10 investors · BiotechnologyRule 506(b)
▶$840KraisedMar 2026 · 10 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Paul KellyExecutive Officer, Director
- Sergio TraversaDirector
- Offering amount
- $2.4M
- Amount sold
- $840K
- First sale
- Feb 2025
- Incorporated
- Corporation, Delaware, 2023
- Federal exemptions
- 06b
▶$5KraisedSep 2023 · 5 investors · BiotechnologyRule 506(b)
▶$5KraisedSep 2023 · 5 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Traversa SergioDirector
- Paul KellyExecutive Officer, Director
- Offering amount
- $5K
- Amount sold
- $5K
- First sale
- Sep 2023
- Incorporated
- Corporation, Delaware, 2023
- Federal exemptions
- 06b
▶$10KraisedSep 2023 · 2 investors · BiotechnologyRule 506(b)
▶$10KraisedSep 2023 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Paul KellyExecutive Officer, Director
- Traversa SergioDirector
- Offering amount
- $10K
- Amount sold
- $10K
- Minimum investment
- $5K
- First sale
- Sep 2023
- Incorporated
- Corporation, Delaware, 2023
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
Frequently asked questions
- How much funding has EnZeta Immunotherapies raised?
- EnZeta Immunotherapies has disclosed $855K raised across 3 rounds.
- Where is EnZeta Immunotherapies headquartered?
- EnZeta Immunotherapies is headquartered in Coral Gables, US.